Drug Topics December 9, 2024
A discussion with Kevin Cowart, PharmD, MPH, BCACP, FCCP, BCPS, assistant professor at the University of South Florida Taneja College of Pharmacy.
Since continuous glucose monitors (CGM) were first introduced in 1999, they have quickly become a mainstay of diabetes management. Research has shown that the devices can lead to reductions in glucose variability, HbA1c levels, average blood glucose levels, and hypoglycemic events, while also increasing a patient’s time spent within the target blood sugar range.1
However, CGMs remain underutilized. According to data published in the journal Clinical Diabetes, around 50% of commercially insured patients with type 1 diabetes do not use a CGM device despite the known benefits. The authors of the study identifying populations with lagging utilization is...
Today's Sponsors
Today's Sponsor